Safety first
Educational only. Not medical advice. The choice between compounded and FDA-approved HRT products should be made with a clinician who can explain the specific clinical rationale.
Overview
“Bioidentical.” “Custom-compounded.” “Tailored to your unique hormonal profile.” These phrases sell millions of dollars of compounded HRT every month. Here is what they do not tell you: the most commonly prescribed FDA-approved HRT products - estradiol and micronized progesterone - are already bioidentical. They are molecularly identical to your own hormones, backed by clinical trials, manufactured under FDA quality controls, and covered by insurance. You do not need to pay more for a compounded product to get bioidentical hormones. You already can, for a fraction of the price.
Key Takeaways
- “Bioidentical” means molecularly identical to human hormones. Estradiol and micronized progesterone ARE bioidentical AND FDA-approved
- Compounded products lack FDA approval, clinical trial data as finished products, and standardized quality control
- NAMS, ACOG, and the FDA recommend FDA-approved bioidentical products over compounded alternatives when both are available
- Compounding has legitimate uses: allergy to excipients (e.g., peanut oil in Prometrium), doses unavailable commercially, or combining products for convenience
- Generic FDA-approved HRT costs $14 to 65 per month. Compounded multi-hormone preparations cost $80-200+/month. The premium does not buy better hormones
When Compounding Is Legitimate
Documented allergy to an inactive ingredient in the FDA-approved product. Clinical need for a dose or formulation not available commercially. Need for a specific combination in a single preparation. These are real clinical situations where compounding serves the patient.
When Compounding Is Marketing
When a compounded estradiol cream is prescribed without discussing FDA-approved alternatives available at lower cost. When every patient receives the same preparation despite the "customized" label. When salivary hormone testing is used to guide frequent dose changes despite NAMS recommending against it. When multiple hormones are bundled into a single preparation without specific evidence-based indications for each component.
Red Flags In Compounding Clinic Marketing
Salivary hormone testing for dose management. NAMS explicitly recommends against it. Saliva levels do not reliably correlate with serum levels or clinical response. Clinics that use salivary testing may test frequently and adjust doses based on results that NAMS considers unreliable for guiding HRT management.
Multi-hormone “optimization” panels. If estradiol, progesterone, testosterone, DHEA, and pregnenolone are prescribed as a standard package without specific clinical indications for each component, the protocol may not reflect the individualized approach that evidence-based guidelines recommend.
Claims that compounded hormones are “safer” or “more natural.” NAMS, ACOG, and the FDA have all directly contradicted this claim. Some compounding pharmacies have been found to have potency and sterility issues during FDA inspections.
“We can customize the exact dose your body needs.” FDA-approved products come in multiple doses. The vast majority of women can be effectively treated with commercially available doses. True customization needs are the exception.
What NAMS Says
NAMS explicitly recommends FDA-approved hormone therapies as the preferred option when available, noting that compounded hormones lack the regulatory oversight, safety testing, and efficacy data of approved products.
Cost Comparison
Generic oral estradiol: $4 to 15 per month. Generic progesterone: $15 to 50 per month. Total FDA-approved regimen: $20 to 65 per month.
Compounded estradiol cream: $40-100+/month. Compounded multi-hormone preparation: $80-200+/month. In most cases, you are paying more for less evidence.
The 503A vs 503B Distinction
Not all compounding pharmacies are the same, and the regulatory difference matters.
503A pharmacies compound individual patient prescriptions based on a specific clinician’s order. They are regulated by state boards of pharmacy. Quality oversight varies significantly by state. There is no federal manufacturing standard. Potency and sterility testing is not universally required.
503B outsourcing facilities register with the FDA and can produce larger batches under more standardized conditions. They must comply with current Good Manufacturing Practice (cGMP) standards, report adverse events to the FDA, and undergo FDA inspection. This is a meaningfully higher quality bar than 503A.
If your clinician prescribes compounded HRT, ask whether the pharmacy is 503A or 503B. If 503A, ask whether it is PCAB-accredited (a voluntary quality standard that exceeds most state board minimums). If the clinician does not know which type of pharmacy they are using or whether it is accredited, that is a gap in their quality oversight.
The FDA has taken enforcement action against compounding pharmacies for potency failures (products containing significantly more or less hormone than labeled), sterility failures (contaminated products), and labeling violations. These are not theoretical risks. They are documented events. FDA-approved products do not have these issues because they are manufactured under federal quality standards with batch testing requirements.
Questions To Ask
- Are you prescribing FDA-approved or compounded products?
- If compounded, what specific clinical reason prevents use of an FDA-approved alternative?
- Is the compounding pharmacy PCAB-accredited?
- How does the cost compare to generic FDA-approved alternatives?
- Do you use saliva or serum testing for monitoring? (If saliva, ask why - NAMS recommends against it.)